Adverse Effects of SARS-CoV-2 Vaccines on Patients Suffering from Non-Communicable Diseases

Bareq N.  Al-Nuaimi; Murtadha Nabil  Abdulghani; Ammar Basim   Al-Assady; Dhiey A. Al-Aameri

doi:10.17605/cajmns.v6i4.2921

Bareq N. Al-Nuaimi Department of Microbiology, College of Medicine, Al-Iraqia University, Baghdad, Iraq
Murtadha Nabil Abdulghani Department of Microbiology, College of Medicine, Mustansiriyah University, Baghdad, Iraq
Ammar Basim Al-Assady Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq
Dhiey A. Al-Aameri Mustansiriyah University, Baghdad, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i4.2921

Keywords: SARS-CoV-2, Vaccines, Hypertension, Diabetes, Rheumatoid Arthritis

Abstract

Vaccination side effects is one of the main social concerns in vaccination decision among population especially among adults who have non-communicable diseases. The aim of the present study is to investigate the effect of three SARS-CoV-2 vaccines presented in Iraq (Pfizer, AstraZeneca-Oxford and Sinopharm) including SARS-CoV-2 infection on the development of some post- vaccination side effects. A total of 414 individuals were included in the present study. Data was collected between January 2022 and March 2022. All individuals are vaccinated by one of the three vaccines that are available in Iraq which are Oxford-AstraZeneca vaccine, Pfizer Biontech vaccine and Sinopharm vaccine. All individuals in the present study were tested for one of the common non-communicable diseases (Hypertension, Allergy, Rheumatoid arthritis, Heart diseases, Diabetes, Kidney diseases and others). The results revealed the prevalence of moderate side effects were in two types of vaccines in Iraq which are Pfizer BioNTech Vaccine and Oxford-AstraZeneca vaccine. However; Sinopharm Vaccine show mild or asymptomatic side effects to all types of non-communicable diseases. Severity was observed in Pfizer BioNTech vaccine only. The side effects of three major SARS-CoV-2 vaccines in Iraqi patients with NCDs, differentiating between those previously infected and those who were not.

References

. Al-Nuaimi BN, Abdul-Ghani MN, Al-Asadi AB, Al-Maadhidi JF, Al-Aameri DA, Hadab MA. Efficacy of Sars-Cov-2 Vaccines on Severity of Coronavirus Disease in Iraq. The International Tinnitus Journal. 2024 Mar 28:68-72.

. M. Gresham L, Marzario B, Dutz J, G. Kirchhof M. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. 2021. ncbi.nlm.nih.gov

. Nikoloski Z, Mohammed Alqunaibet A, Abdulrahman Alfawaz R, Saeed Almudarra S et al. Covid-19 and non-communicable diseases: evidence from a systematic literature review. 2021. ncbi.nlm.nih.gov

. M. Attash H, M. Al-Obaidy L, Kh. Al-Qazaz H. Which Type of the Promising COVID-19 Vaccines Produces Minimal Adverse Effects? A Retrospective Cross-Sectional Study. 2022. ncbi.nlm.nih.gov

. Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. 2022. ncbi.nlm.nih.gov

. Al-Qerem W, Hammad A, Hussein Alsajri A, Waleed Al-Hishma S et al. COVID-19 Vaccination Acceptance and Its Associated Factors Among the Iraqi Population: A Cross Sectional Study. 2022. ncbi.nlm.nih.gov

. G. Shareef L, Fawzi Al-Hussainy A, Majeed Hameed S. COVID-19 vaccination hesitancy among Iraqi general population between beliefs and barriers: An observational study. 2022. ncbi.nlm.nih.gov

. Daba C, Asefa L, Lemma H, Atamo A et al. Why Does COVID-19 Vaccine Acceptance Rate Remain Low Among Patients with Chronic Diseases? Evidences from Public Hospitals of Ethiopia. 2022. ncbi.nlm.nih.gov

. J. Saadh M, Aldeen Jaber S. Efficacy of COVID-19 vaccines. 2022. ncbi.nlm.nih.gov

. Nevola R, Criscuolo L, Beccia D, Delle Femine A et al. Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination. 2023. ncbi.nlm.nih.gov

. S. J. Alatrany S, Muwafa Falaiyah A, Hammlee Maarij Zuhairawi R, Ogden R et al. A cross-sectional analysis of the predictors of COVID-19 vaccine uptake and vaccine hesitancy in Iraq. 2023. ncbi.nlm.nih.gov

. Liu Y, Yuan W, Zhan H, Kang H et al. SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China. 2023. ncbi.nlm.nih.gov

. Comirnaty: Product Information (PDF) (Report). Amsterdam, Netherlands: European Medicines Agency (EMA). Archived (PDF) from the original on 24December 2020. Available fromhttps://www.ema.europa.eu/en/documents/product-information/comirnaty epar-product-information_en.pdf Accessed at April 18th 2022

. Al-Asadi AB, Al-Nuaimi BN, Abdul-Ghani MN, Al-Maadhidi JF. Immune response among different types of SARS-CoV-2 vaccines in Iraq. J Comm Dis. 2022:103-8.

. Al-Nuaimi BN, Al-Azzawi RH. Correlation between MicroRNA-155 Expression and Viral Load in Severe COVID-19 Patients. J. Commun. Dis. 2024;56(4):4.

. Soheili M, Khateri S, Moradpour F, Mohammadzedeh P, Zareie M, Mortazavi SM, Manifar S, Kohan HG, Moradi Y. The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis. Annals of clinical microbiology and antimicrobials. 2023 May 19;22(1):42.

. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, Turner RJ. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines. 2021 May 6;9(5):467.

. Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, Lv T. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. BMC infectious diseases. 2024 Feb 21;24(1):234.

. Evans SJ, Jewell NP. Vaccine effectiveness studies in the field. New England Journal of Medicine. 2021 Aug 12;385(7):650-1.

. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, Shaban D, Al Khames Aga LA, Agha MY, Traqchi M. Safety of COVID‐19 vaccines. Journal of medical virology. 2021 Dec;93(12):6588-94.

. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA network open. 2021 Dec 1;4(12):e2140364-.

. Hromic-Jahjefendic A, Barh D, Uversky V, Aljabali AA, Tambuwala MM, Alzahrani KJ, Alzahrani FM, Alshammeri S, Lundstrom K. Can COVID-19 vaccines induce premature non-communicable diseases: where are we heading to? Vaccines 2023; 11: 208 [Internet]. 2023

. Saleh AM, Shabila NP. A Survey of the Side Effects of Pfizer/BioNTech COVID-19 Vaccine among Vaccinated Adults in Iraq. Asia Pacific Journal of Health Management. 2023 Dec 1;18(3):197-206.

. Salman HA, Hussin AM, Hassan AH, Al Sabbah H, Al-Khafaji K. The prevalence of potential side effects of COVID-19 vaccines among vaccinated Iraqi people: a prospective cross-sectional study. Arab Gulf Journal of Scientific Research. 2024 Oct 23;42(3):1221-9.

. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021 Sep 1;15(5):102207.